Table 1 Demographic information of cancer patients
From: Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
|  | Total (n = 160) | Male (n = 85) | Female (n = 75) | |||
|---|---|---|---|---|---|---|
| Â | n | (%) | n | (%) | n | (%) |
Age Group (years) | ||||||
 30–44 | 11 | 6.9 | 1 | 1.2 | 10 | 13.3 |
 45–59 | 35 | 21.9 | 12 | 14.1 | 23 | 30.7 |
 60–74 | 96 | 60.0 | 58 | 68.2 | 38 | 50.7 |
 75–85 | 18 | 11.3 | 14 | 16.5 | 4 | 5.3 |
Race | ||||||
 African American/Black | 6 | 3.8 | 2 | 2.4 | 4 | 5.3 |
 Asian Chinese | 3 | 1.9 | 2 | 2.4 | 1 | 1.3 |
 Asian Japanese/White | 1 | 0.6 | 1 | 1.2 | 0 | 0.0 |
 Other | 2 | 1.3 | 1 | 1.2 | 1 | 1.3 |
 White | 148 | 92.5 | 79 | 92.9 | 69 | 92.0 |
Vaccine Type | ||||||
 Moderna | 62 | 38.8 | 34 | 40.0 | 28 | 37.3 |
 Pfizer | 98 | 61.3 | 51 | 60.0 | 47 | 62.7 |
Cancer type | ||||||
 CLL | 54 | 33.8 | 40 | 47.1 | 14 | 18.7 |
 Lung | 29 | 18.1 | 18 | 21.2 | 11 | 14.7 |
 Breast | 30 | 18.8 | 0 | 0.0 | 30 | 40.0 |
 CLL/Breast | 2 | 1.3 | 0 | 0.0 | 2 | 2.7 |
 Non–Hodgkin’s Lymphoma | 45 | 28.1 | 27 | 31.8 | 18 | 24.0 |
Anti–B cell therapy | ||||||
 CLL | 28 | 17.5 | 23 | 27.1 | 5 | 6.7 |
 Non–Hodgkin’s Lymphoma | 19 | 11.9 | 11 | 12.9 | 8 | 10.7 |
Anti–PD–1/PD–L1 | ||||||
Lung | 26 | 16.3 | 17 | 20.0 | 9 | 12.0 |
Breast | 2 | 1.3 | 0 | 0.0 | 2 | 2.7 |